Nebenwirkungen · Wegovy
Wegovy 1.5 mg tablets Wegovy 4 mg tablets Wegovy 9 mg tablets Wegovy 25 mg tablets · Abschnitt 4.8 · PDF-Seite 47
HOS-147362 · Präparat HOS-099634
Gastrointestinal adverse reactions The events were most frequently reported during dose escalation. Over the 64 weeks trial period, nausea occurred in 46.6% of patients when treated with oral semaglutide (18.6% for placebo), vomiting in 30.9% (5.9% for placebo), dyspepsia in 18.1% (8.8% for placebo), diarrhoea in 17.6% (8.8% for placebo), and abdominal pain in 16.7% (7.8% for placebo). Most events were mild to moderate in severity and of short duration. Constipation occurred in 20.1% of patients treated with semaglutide (9.8% for placebo) and was mild to moderate in severity and of longer duration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 6f8e067129d649801783268b658d9865fbec1c9eec2ef512e1d1e2b3e75277fb · Zeichen 5855–6460 im Abschnitt